Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive, Persistent, or Recurrent Cutaneous T-Cell Lymphoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Alternate Title

Phase II Study of Suberoylanilide Hydroxamic Acid in Patients With Progressive, Persistent, or Recurrent Stage IB-IV Cutaneous T-Cell Lymphoma

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentClosed18 and overNCI, Pharmaceutical / IndustryUCLA-0412112-01
MERCK-CL-01-0303 (2), NCT00091559, MERCK-001-02

Trial Description


Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive, persistent, or recurrent cutaneous T-cell lymphoma.


Eligibility criteria include the following:

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.


Patients will receive suberoylanilide hydroxamic acid by mouth once a day. Treatment may continue for as long as benefit is shown.

Patients will be evaluated within 4 weeks and once a year thereafter.


For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Jonsson Comprehensive Cancer Center at UCLA

Lauren Pinter-Brown, MD, Protocol chair
Ph: 818-364-3205

Registry Information

Official TitlePhase IIB Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-Cell Lymphoma
Registered in ClinicalTrials.govNCT00091559
Date Submitted to PDQ2005-05-11
Information Last Verified2007-07-30
NCI Grant/Contract NumberP30-CA16042